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DOI 10.1016/j.chembiol.2007.01.004In the last several years, researchers
have increasingly focused on using
the innate immune system to fight dis-
ease. Considered the body’s first line
of defense, the innate immune system
is stimulated by a broad spectrum of
molecules usually found on or in path-
ogens, and it triggers an inflammatory
response and spurs the adaptive
immune system to generate lasting
immunity. The innate immune sys-
tem features ‘‘toll-like receptors’’ (TLR)
that are expressed on the surfaces
of antigen-presenting, dendritic, and
other cells. Ten human TLRs that re-
spond to a variety of pathogens have
been identified so far. Most TLRs inter-
act with the proteins, liposaccharides,
and lipopeptides expressed on cell
surfaces, but some are able to detect
intracellular elements such as nucleic
acids.
A number of biotech companies, in
collaboration with pharma, are now
exploring the possibilities for manipu-
lating immunity by developing TLR-
based therapeutic agents for ailments
such as hepatitis B and C, HIV, certain
cancers, allergies, asthma, and auto-
immune diseases. However, elucidat-
ing the path by which TLRs stimulate
and direct innate immunity’s ‘‘master
switchboard’’ is tricky, as it is such
a pervasive system.
Funny-Looking Fruit flies
Toll-like receptors acquired their name
because in 1988 aGerman researcher,
future Nobel laureate Christiane
Nusslein-Volhard, stumbled across
peculiarly misshapen fruit fly embryos.
A link to the immune system was es-
tablished when it became apparent
that these fruit flies, missing a func-
tional protein, were more susceptible
to fungal infection. Nusslein-Volhard
termed the gene that caused this
‘‘toll,’’ for strange or wondrous. The
attributes of the toll genes took a while
to be appreciated; certain drugs, like
3M’s topical cream Aldara (imiquimod)
for basal cell carcinoma, HPV, and
genital warts, were marketed before
researchers knew they worked via
TLRs.
Flu Symptoms for a Year
Chronic hepatitis C (HCV), a viral dis-
ease that destroys the liver, affects
170 million people worldwide, accord-
ing to the World Health Organization.
The current treatment is to inject pegy-
lated interferon in conjunction with
ribavirin for close to a year to stimulate
and maintain an antiviral immune
response. ‘‘It is a difficult regime to
tolerate,’’ says Devron Averett, Ph.D.,
chief scientific officer of San Diego-
based Anadys (http://www.anadys.
com). According to Averett, the treat-
ment produces nasty flu-like symp-
toms and typically works about
50%–60% of the time. ‘‘We thought it
would be possible to stimulate innate
immunity through toll-like receptor-
7,’’ said Averett. ‘‘It would be an oral,
rather than injectable, therapy and
have fewer side effects. That is the ba-
sis for our partnership with Novartis
around ANA975.’’ This isatoribine-
based compound for hepatitis B and
C stimulates TLR7 to cause release
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important to the immune cascade
into the bloodstream. The company’s
preclinical pipeline also includes
ANA773, an oral TLR7 prodrug for cer-
tain types of cancer, and ANA380 for
chronic hepatitis B, which has com-
pleted Phase II clinical trials. Anadys
is also pursuing preclinical antivirals
for human immunodeficiency virus
(HIV) infection.
‘‘Toll-like receptors are a fairly
recent scientific understanding,’’ said
Averett. ‘‘What we did know is that isa-
toribine stimulated innate immunity.’’
Publications by researchers including
immunologist Charles Janeway at
Yale as well as other data on lipopoly-
saccharide-resistant mice from Bruce
Beutler at Scripps gave the company
a better understanding of how their
compound worked.
The body has many TLR7 receptors
in the gut, but swallowing a slug of isa-
toribine will cause symptoms similar to
food poisoning. Through medicinal
chemistry sleight-of-hand, Anadys de-
veloped a ‘‘prodrug,’’ a masked oral
form of isatoribine which can be
absorbed in the gut without causing
nausea, and which becomes active
only in the bloodstream.
The Financial Picture
Anadys is a publicly traded company,
has 94 employees, and was estab-
lished in its present incarnation in
2000 by Kleanthis G. Xanthopoulos,
Ph.D., and Devron Averett. The com-
pany garnered a $20 million licensing
payment in 2005 from Novartis, and
another $10million milestone payment
upon the acceptance of the IND appli-
cation by the FDA. A potential $540
million in milestone payments rides
on getting ANA975 approved as
a drug. Anadys has additional collabo-
rations with LG Life Sciences and
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Immunologists are mindful of the case
of TeGenero’s TGN1412, a CD28 ago-
nist, which caused the volunteers who
received it in a Phase 1b trial during the
spring of 2006 to develop massive in-
flammation and a sepsis-like response
due to overproduction of cytokines.
In June 2006, ANA975 was under-
going a 28 day Phase 1b trial in HCV
patients when the preclinical toxicol-
ogy data in a 13 week trial of rats and
monkeys showed an unusually high
level of lymphocyte proliferation and
enlarged lymph nodes. Although the
drug was seemingly well tolerated in
the human study, Anadys halted dos-
ing and notified the FDA, which put
the brakes on the company’s IND ap-
plication. Anadys is now conducting
a new animal toxicity study using a
crystalline form of the drug supplied
by Novartis. While ANA975 targets
a different area of immune response
than TGN1412, the symptoms of im-
mune system overstimulation were
similar enough to warrant a deeper
look.
Taking Another Toll Road
Wellesley, MA-based Coley Pharma-
ceutical Group, Inc. (http://www.
coleypharma.com), is named after
Dr. William Coley, who in the late
1800’s observed that patients with
local infections had remissions in can-
cer. Dr. Arthur Krieg founded Coley in
1997. In his research at the University
of Iowa and VA Medical Center, he
discovered that synthetic oligodeoxy-
nucleotides with the CpG (cytidine-
phosphate-guanine) motif stimulate
immune cells. This CpG sequence is
methylated in humans (which avoids
immune stimulation), but not in viruses
and bacteria. Unknowingly, he discov-
ered a TLR9 agonist. Coley’s com-
pound Actilon is now in Phase II trials
for hepatitis C in patients unresponsive
to conventional treatments.
Coley’s TLR9 program for cancer
is the company’s most advanced.
‘‘When we inject the CpG or TLR ago-
nist into someone who has cancer, it is
like waking the immune system up and
saying here is an infection,’’ said Krieg.
‘‘At least theoretically if it is activated in
the right way it should be able to kill tu-
mors. We have been able to prove this2 Chemistry & Biology 14, January 2007in mice’’ [1]. According to Krieg,
a problem with the classical approach
of developing a tumor vaccine is
knowing exactly what all the tumor an-
tigens are. Stimulating the dendritic
cells of the innate immune system
could bypass that obstacle. ‘‘Dendritic
cells are part of the innate immune
system but stimulate adaptive immune
responses, especially killer T cells,’’
said Krieg.
Pfizer paid $60 million upfront and
could make a potential $455 million
in additional milestone payments for
CpG 7909. PF-3512676, as Pfizer
renamed it, is in Stage III clinical trials,
administered in conjunction with stan-
dard chemotherapy drugs, and has
shown promising results in non-small
cell lung cancer (and Pfizer hopes for
multiple oncology indications as well,
including breast cancer).
Coley has licensed the know-how
surrounding CpG 7909 to Glaxo-
SmithKline as an adjuvant for breast,
lung, and prostate cancer vaccines.
Coley is also jointly developing TLR9
agonists to treat asthma and rhinitis
with Sanofi Aventis. Coley bases its
allergy program on the ‘‘hygiene
hypothesis’’ that the rising incidence
of allergies in industrialized countries
is due to insufficient stimulation of the
immune system in childhood, and
that it may be corrected via using
CpG to mature the immune system.
Coley has focused on TLR9 because
‘‘[it] has the most narrow pattern of ex-
pression,’’ Krieg said. If the immune
system is activated too broadly, ‘‘One
manifestation can be a cytokine storm,
another one can be an autoimmune
disease.’’ According to Krieg, Coley
and other companies working on
TLR9 have treated thousands of peo-
ple with TLR9 agonists with no major
problems. Under a grant from NIAID,
Coley is also investigating the possibil-
ity of stimulating TLRs 3, 7, and 8 with
RNA from viruses and bacteria.
Boosting the Immune Response
One of the first uses for TLR agonists
was as adjuvants for vaccines. Adju-
vants are molecules that typically acti-
vate innate immune cells, particularly
dendritic cells, and when used in con-
junction with an antigen stimulate
a stronger adaptive immune response,ª2007 Elsevier Ltd All rights reservedincluding antibodies and, in some
cases, killer T cells. TLR agonists
would seemingly make excellent can-
didates, because TLRs have the ability
to stimulate some of the major regula-
tory lymphocytes and activate both
the innate and the adaptive immune
systems.
While Anadys and Coley are more
concerned with developing drugs,
companies like Berkeley-based
Dynavax Technologies (http://www.
dynavax.com) is involved in develop-
ing TLR9-based adjuvants for vac-
cines. Idera Pharmaceuticals (http://
www.iderapharma.com), located in
Cambridge,MA, just signed a licensing
deal with Merck & Co. to use agonists
of TLR9, TLR7, and TLR8 for vaccines
for cancer, infectious diseases, and
Alzheimer’s disease.
Follow Those Mouse Tracks
While TLR-based programs look
promising, all must contend with the
fact that what works in animal studies
may not map onto the human immune
system closely enough for comfort.
Current research may well indicate
that the toll gates are not such straight-
forward passages to immune control.
To wit: work by Jean-Laurent Casa-
nova’s research group at the Necker
Medical School in Paris showed that
a small group of unrelated patients
who had inherited functional defects
in a signaling pathway downstream
of TLRs did not respond to eight of
the nine receptor-specific ligands
tested [2]. The patients suffered from
pyogenic bacteria infections with
minimum inflammatory responses.
Another group of patients with im-
paired downstream signaling from
TLRs 3, 7, 8, and 9 were only suscep-
tible to herpes simplex virus encepha-
litis, but otherwise healthy [3]. These
findings were surprising because
mice with similar defects show gross
susceptibility to microbial, viral, and
fungal infections. These results sug-
gest that TLR systems in humans
may be redundant andmay not neces-
sarily play as crucial a role in the innate
immune system as previously thought.
Drugs agonizing and antagonizing
TLRs are being developed even as
the rudimentary roles for the receptors
in immunity are being uncovered.
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treating an amazing spectrum of mal-
adies, possibly with fewer side effects
than current drugs. But in the case of
the immune system, it is wise to pro-
ceed with caution. So in short: look
both ways before taking the toll road.REFERENCES
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